142 related articles for article (PubMed ID: 18712519)
1. Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir.
López Galera RM; Ribera Pascuet E; Esteban Mur JI; Montoro Ronsano JB; Juárez Giménez JC
Eur J Clin Pharmacol; 2008 Dec; 64(12):1235-6. PubMed ID: 18712519
[No Abstract] [Full Text] [Related]
2. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.
Manosuthi W; Sungkanuparph S; Ruxrungtham K; Prasithsirikul W; Athichathanabadi C; Tantisiriwat W; Bowonwatanuwong C; Chumpathat N; Chaovavanich A
J Acquir Immune Defic Syndr; 2008 Jan; 47(1):127-9. PubMed ID: 18156994
[No Abstract] [Full Text] [Related]
4. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.
King JR; Kakuda TN; Paul S; Tse MM; Acosta EP; Becker SL
J Clin Pharmacol; 2007 Feb; 47(2):201-8. PubMed ID: 17244771
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?
Furtek KJ; Crum NF; Olson PE; Wallace MR
J Acquir Immune Defic Syndr; 2006 Mar; 41(3):394-6. PubMed ID: 16540945
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
[TBL] [Abstract][Full Text] [Related]
8. Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen.
von Hentig N; Kaykhin P; Stephan C; Babacan E; Stürmer M; Staszewski S; Lötsch J
Antimicrob Agents Chemother; 2008 Jun; 52(6):2273-5. PubMed ID: 18411323
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S
Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
[TBL] [Abstract][Full Text] [Related]
10. Atazanavir: a new protease inhibitor to treat HIV infection.
Musial BL; Chojnacki JK; Coleman CI
Am J Health Syst Pharm; 2004 Jul; 61(13):1365-74. PubMed ID: 15287232
[TBL] [Abstract][Full Text] [Related]
11. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
12. Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir.
Guiard-Schmid JB; Poirier JM; Bonnard P; Meynard JL
J Acquir Immune Defic Syndr; 2006 Mar; 41(3):393-4; author reply 394. PubMed ID: 16540944
[No Abstract] [Full Text] [Related]
13. Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults.
von Hentig N; Lötsch J
Antimicrob Agents Chemother; 2009 Aug; 53(8):3524-7. PubMed ID: 19528289
[TBL] [Abstract][Full Text] [Related]
14. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
15. Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.
DiCenzo R; Peterson DR; Cruttenden K; Mariuz P; Rezk NL; Hochreiter J; Gelbard H; Schifitto G
Antimicrob Agents Chemother; 2008 Sep; 52(9):3035-9. PubMed ID: 18573930
[TBL] [Abstract][Full Text] [Related]
16. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
Zhu L; Persson A; Mahnke L; Eley T; Li T; Xu X; Agarwala S; Dragone J; Bertz R
J Clin Pharmacol; 2011 Mar; 51(3):368-77. PubMed ID: 20457590
[TBL] [Abstract][Full Text] [Related]
17. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
Karlström O; Josephson F; Sönnerborg A
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):417-22. PubMed ID: 17159658
[TBL] [Abstract][Full Text] [Related]
18. Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.
Poirier JM; Robidou P; Jaillon P
Ther Drug Monit; 2005 Apr; 27(2):186-92. PubMed ID: 15795650
[TBL] [Abstract][Full Text] [Related]
19. From grapefruit juice to ritonavir.
TreatmentUpdate; 2001; 12(12):5-6. PubMed ID: 11570093
[No Abstract] [Full Text] [Related]
20. Anti-HIV agents. Atazanavir and saquinavir.
TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
[No Abstract] [Full Text] [Related]
[Next] [New Search]